Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global benign prostatic hyperplasia surgical treatment market was valued at 10.5 billion in 2024 and is expected to reach US$ 16.5 billion by 2033, ...

ST. LOUIS — As many men get older, their prostate gland enlarges, which may squeeze the urethra and obstruct the flow of urine. Other risk factors for Benign Prostatic Hyperplasia (BPH) include family ...

PHILADELPHIA (WPVI) -- Benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland, is the most common benign tumor found in men. BPH produces symptoms by obstructing the flow ...

Your urologist will use several tests to determine how severe your BPH is and whether it affects your bladder health. They may recommend watchful waiting if your BPH is mild. Watchful waiting means ...

Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a ...

These new findings are important as α-blockers (ABs) are the most prescribed class of medications for patients with benign prostatic hyperplasia (BPH), but the cardiovascular safety profile of this ...

Benign prostatic hyperplasia (BPH) remains a significant clinical condition affecting ageing men worldwide, characterised by enlargement of the prostate gland and associated lower urinary tract ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Drug Used for Enlarged Prostate Tied to High Glaucoma Risk The use of alpha-blockers for benign prostatic hyperplasia is tied to an increased risk of developing acute angle-closure glaucoma, a study ...

Extracts of the berries of saw palmetto, a small palm tree native to the southeastern U.S., are used widely to treat benign prostatic hyperplasia (BPH). In this randomized trial conducted in ...

Laborie Medical Technologies Inc. continued a string of recent deals with an agreement to acquire Urotronic Inc. for $255 million cash up front with an additional $345 million in payments contingent ...